The goal of this clinical trial is to evaluate the proportion of ureteral stones ≤4 mm that pass spontaneously within 4 and 8 weeks and assess if pain, blood test (S-creatinine), stone size, stone location and hydronephrosis can predict stone passage. The participants will be asked to fill in a questionare regarding symptoms, give a blood test and undergo a follow-up computed tomography.
All patients with a diagnosis of ureteral stone ≤4 mm at the Emergency Department in Helsingborg will be asked to participate. If they give consent data regarding age, gender, stone size, stone location, hydronephrosis, S-creatinine, treatments and results from the follow up CT is extraced from the medical records.
Study Type
OBSERVATIONAL
Enrollment
1,600
Department of Urology
Helsingborg, Sweden
Department of Urology, KI Huddinge
Stockholm, Sweden
Number of ureteral stones ≤ 4mm that pass spontaneously
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
Number of participants with residual pain
Residual pain is measured with VAS (visual analogue scale), values 0-10. VAS 0 = no pain and VAS 10 = worst possible pain.
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
QoL form including sick leave and return to full ADL
Questionnaire specifically designed for this study, including questions about pain (regarding pain: how often, how severe/ VAS, need for pain medication) and the ability/ inability to work as usual. VAS: visual analougus scale 0-10, 0 = no pain and 10 = worst possible pain.
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
Proportion of ureteral stone that have passed according to anatomical localisation, S-creatinine and presence of hydronephrosis.
Time frame: From enrolement to passage of the stone or maximum 8 weeks.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.